STAMFORD, Conn.--(BUSINESS WIRE)-- Sema4, a health information company providing advanced genomic testing, today announced the appointment of Alan B. Copperman, MD, as Chief Medical Officer. Dr. Copperman is Director of the Division of Reproductive Endocrinology and Infertility and Vice Chairman of the Department of Obstetrics, Gynecology and Reproductive Science at the Icahn School of Medicine at Mount Sinai, and is Managing Partner at Reproductive Medicine Associates of New York.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171003005497/en/
Alan Copperman, MD, Chief Medical Officer of Sema4 (Photo: Business Wire)
“Alan is a renowned expert and deeply experienced clinician, highly regarded by his peers and patient advocacy organizations for his commitment to patient-focused and data-driven care,” said Eric Schadt, PhD, Chief Executive Officer of Sema4. “I look forward to partnering closely with Alan to translate our scientific vision of merging advanced genomic testing and big data analytics into clinical diagnostics that help improve the treatment and prevention of disease.”
In addition to his positions at Mount Sinai, Dr. Copperman serves as Medical Director of Reproductive Medicine Associates of New York, one of the largest and most prestigious in vitro fertilization centers in the United States. He has published numerous manuscripts and book chapters on reproductive medicine, and has co-authored hundreds of scientific abstracts on infertility, in vitro fertilization, egg freezing, ovum donation, and genetics. Dr. Copperman was named to New York Magazine’s list of Best Doctors 16 years in a row, and has been recognized annually by Castle Connolly and SuperDocs as one of the top fertility doctors. Dr. Copperman trained in Obstetrics and Gynecology at Yale-New Haven Hospital and completed his specialty training in Reproductive Endocrinology at the Icahn School of Medicine at Mount Sinai.
“I truly believe that optimal healthcare should be based on a sophisticated collaboration among physicians, researchers, data scientists, and engineers,” said Dr. Copperman. “The idea of using big data and genomics to revolutionize oncology and reproductive medicine is really exciting, and today’s medical decisions and products must be precise and patient-specific. I take tremendous pride in taking care of the patient in front of me, and look forward to working with Sema4 to create tools and information to help women and men everywhere achieve their reproductive goals. Whether that means fertility preservation, infertility treatment, or figuring out how to have a healthy baby, I believe that the team at Sema4 is absolutely on the right track.”
Sema4 is a next generation health information company, spun out of the Mount Sinai Health System, that provides advanced genomic testing and merges big data analytics with clinical diagnostics. Our team is creating practical tools that help patients, clinicians, and researchers better diagnose, treat, and prevent disease.
Sema4 is constructing a more comprehensive picture of health by combining a wealth of clinical experience that informs the answers that patients and providers are seeking, the world-class academic research that illuminates new directions, and the pioneering information science that puts all the pieces together.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171003005497/en/